Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The recommended dose of dulaglutide is 0.75 mg once weekly as monotherapy.1
The recommended dose of dulaglutide is 1.5 mg once weekly as add-on therapy.1
For potentially vulnerable populations 0.75 mg once weekly can be considered as a starting dose.1
When dulaglutide is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued. 1
When dulaglutide is added to existing metformin and/or SGLT2i therapy, the current dose of metformin and/or SGLT2i can be continued. 1
When dulaglutide is added to existing therapy of a sulphonylurea or insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia.1
The use of dulaglutide does not require blood glucose self‑monitoring. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea or insulin, particularly when dulaglutide therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.1
Dulaglutide Dosage Rationale
The CHMP noted, that when used as monotherapy or in combination with other antihyperglycemic medications, dulaglutide administered once weekly produced a significant and clinically relevant effect on
the primary endpoint of change in glycated hemoglobin (HbA1c) from baseline, and
secondary endpoints. 2
Treatment with dulaglutide 1.5 mg once weekly was shown to be slightly more efficacious than dulaglutide 0.75 mg once weekly. However, treatment with dulaglutide 0.75 mg also achieved clinically relevant reductions in HbA1c with consistent results on secondary glycemic endpoints. Conversely, treatment with dulaglutide 0.75 mg resulted in a slightly better tolerability and safety profile than dulaglutide 1.5 mg 2.
The tolerability and safety profile of dulaglutide as monotherapy was similar to metformin but overall more favorable with the dulaglutide 0.75 mg dose with generally less gastrointestinal effects and a lower risk of hypoglycemia 2. The risk-to-benefit ratio was greater at the lower dose of dulaglutide 0.75 mg when used alone in patients who could not take metformin or when used in elderly patients over 75 years of age.2,3
Based on their assessment, the CHMP concluded that
dulaglutide 0.75 mg once weekly be approved for the monotherapy indication, and
dulaglutide 1.5 mg once weekly be approved as add-on therapy with dulaglutide 0.75 mg once weekly suggested as a starting dose for add-on therapy for potentially vulnerable patients 2.
2. Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency. Assessment report: Trulicity. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf. Published September 25, 2014. Accessed November 27, 2017.
3. European Medicines Agency. EPAR summary for the public: Trulicity. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002825/WC500179472.pdf. Updated November 2014. Accessed November 27, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002825/WC500179472.pdf
EU = European Union
CHMP = Committee for Medicinal Products for Human Use
SGLT2i = sodium-glucose co-transporter 2 inhibitor
Datum fӧr senaste ӧversyn 2017 M11 27